I am a
Home I AM A Search Login

Papers of the Week


Papers: 1 Jun 2019 - 7 Jun 2019


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2019 Jun 03


J Headache Pain


20


1

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.

Authors

Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U
J Headache Pain. 2019 Jun 03; 20(1):66.
PMID: 31159727.

Abstract

Monoclonal antibodies (mAbs) targeting the CGRP pathway are safe and efficacious therapies for the prevention of migraine. In this study we assessed the effects of discontinuation of preventive erenumab and galcanezumab treatment in patients with chronic migraine.